Three, each for its own reason. AI that recommends chemotherapy dose changes was removed because it carries FDA software-as-a-medical-device risk that would change the platform's whole regulatory posture; Burna AI suggests grades and attribution for a clinician to review and sign, and treatment decisions stay with the clinician. Tumor response reads such as RECIST were removed because they need a separate framework and break the same-engine logic that runs from trial to postmarket. The sponsor-cloud deployment design was withdrawn in August 2026 and replaced by Protocol Studio, which reads a trial's protocol for the research sites that already hold it.
Interactive demo
Try Burna right now, no sign up required.